WallStSmart

Abbott Laboratories (ABT)vsInsulet Corporation (PODD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1537% more annual revenue ($44.33B vs $2.71B). ABT leads profitability with a 14.7% profit margin vs 9.1%. ABT appears more attractively valued with a PEG of 1.52. PODD earns a higher WallStSmart Score of 57/100 (C).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

PODD

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 7.5Value: 4.7Quality: 6.8
Piotroski: 5/9Altman Z: 2.31
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
PODDSignificantly Overvalued (-452.8%)

Margin of Safety

-452.8%

Fair Value

$45.38

Current Price

$216.00

$170.62 premium

UndervaluedFair: $45.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

PODD1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.2%10/10

Revenue surging 31.2% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PODD4 concerns · Avg: 3.5/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Price/BookValuation
10.0x4/10

Trading at 10.0x book value

EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

P/E RatioValuation
62.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PODD

The strongest argument for PODD centers on Revenue Growth. Revenue growth of 31.2% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : PODD

The primary concerns for PODD are PEG Ratio, Price/Book, EPS Growth. A P/E of 62.1x leaves little room for execution misses.

Key Dynamics to Monitor

ABT profiles as a value stock while PODD is a hypergrowth play — different risk/reward profiles.

PODD carries more volatility with a beta of 1.44 — expect wider price swings.

PODD is growing revenue faster at 31.2% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

PODD scores higher overall (57/100 vs 51/100) and 31.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Insulet Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.

Want to dig deeper into these stocks?